Home  Index  News  Study suggests GLP-1 analogues do not raise breast cancer risk

Study suggests GLP-1 analogues do not raise breast cancer risk

Study suggests GLP-1 analogues do not raise breast cancer risk
Women with type 2 diabetes who take glucagon-like peptide-1 (GLP-1) analogues do not have a higher risk of breast cancer than those who take dipeptidyl peptidase-4 (DPP-4) inhibitors, results from a cohort study suggest.

Using data from the UK Clinical Practice Research Datalink involving 44,984 women who were newly treated with glucose-lowering drugs between 1 January 2007 and 31 March 2015, researchers found that breast cancer rates did not differ between those taking GLP-1 analogues and DPP-4 inhibitors over a mean follow-up of 3.5 years.

Date: 7/31/2016
Source : pharmaceutical-journal


Darou Darman Pasargad Address :
No. 53, Amir Bldg, Baharan 1st St, Farahzadi Blvd, Saadat Abad, 1998939413, Tehran, Iran
Tel :
+98 21 88567958
Fax :
+98 21 88693778
© copyright 2016 Darou Darman Pasargad Co ALL RIGHTS RESERVED